Artios Pharma Raises $33.2M in Series A Funding

Artios Pharma, a Cambridge, UK-based developer of novel cancer treatments targeting the DNA Damage Response (DDR), has raised $33.2 million (£25 million) in Series A funding. The round was led by SV Life Sciences and included participation from Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios intends to use the funds to build a pipeline of DDR therapies targeted against cancer and to progress its lead program, Pol-theta, into the clinic. The company was established in May 2016 by CEO Dr. Niall Martin and is focused on developing treatments for cancer through a partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK).

Artios Pharma Secures $33.2M Series A Funding for Cancer Treatments

Artios Pharma is a Cambridge, UK-based developer of novel cancer treatments targeting the DNA Damage Response (DDR). Established in May 2016 by CEO Dr. Niall Martin, Artios is an independent DDR company focused on developing treatments for cancer through a partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with DNA repair researchers worldwide. The company has in-licensed two programs against novel targets, Pol-theta and a second target, as yet undisclosed, from CRT. Both programs are in the drug discovery phase.

A developer of novel cancer treatments targeting the DNA Damage Response (DDR).

9 years ago

Artios Pharma Secures $33.2M Series A Funding for Cancer Treatments

Covered on